109P Prognostic impact of target-directed therapies in biliary tract cancer patients harboring molecular alterations
Silvia Camera(Vita-Salute San Raffaele University), A. Casadei-Gardini(IRCCS Ospedale San Raffaele), Oluseyi Abidoye(Mayo Clinic), Anna Saborowski(Medizinische Hochschule Hannover), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Caterina Vivaldi(Scuola Superiore Sant'Anna), T. Pressiani(IRCCS Humanitas Research Hospital), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), L. Rimassa(IRCCS Humanitas Research Hospital), Jessica Lucchetti(Campus Bio Medico University Hospital), Mario Domenico Rizzato(University of Padua), Federico Rossari(Vita-Salute San Raffaele University), J.W. Kim(Seoul National University Bundang Hospital), Frederik Peeters, F. Lo Prinzi(Università Campus Bio-Medico), M. Rimini(IRCCS Ospedale San Raffaele), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), Tatsunari SATAKE(National Cancer Center Hospital East), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna)
Cited by 0
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
|The Lancet Oncology|2022|268
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
|Lung Cancer|2019|158
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors
|The Oncologist|2014|103